Paul J. Diaz's Insider Trades & SAST Disclosures
Paul J. Diaz's most recent trade in Myriad Genetics, Inc. was a trade of 52,682 Common Stock done at an average price of $10.0 . Disclosure was reported to the exchange on March 22, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paul J. Diaz.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 52,682 | 936,983 (1%) | 0% | 10.0 | 527,347 | Common Stock |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 26,827 | 891,844 (1%) | 0% | 10.0 | 267,733 | Common Stock |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.01 per share. | 22 Mar 2025 | 19,859 | 989,665 (1%) | 0% | 10.0 | 198,789 | Common Stock |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.98 per share. | 22 Mar 2025 | 18,312 | 918,671 (1%) | 0% | 10.0 | 182,754 | Common Stock |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 14 Mar 2025 | 37,564 | 1,039,642 (1%) | 0% | 10.1 | 378,269 | Common Stock |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.07 per share. | 14 Mar 2025 | 30,118 | 1,009,524 (1%) | 0% | 10.1 | 303,288 | Common Stock |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2025 | 114,828 | 1,077,206 (1%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Diaz Paul J. | Director, President and CEO | 11 Oct 2024 | 15,000 | 962,378 (1%) | 0% | 22.9 | 343,950 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 11 Sep 2024 | 15,000 | 977,378 (1%) | 0% | 26.7 | 400,800 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2024 | 50,980 | 992,378 (1%) | 0% | 28.2 | 1,436,616 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2024 | 22,808 | 1,043,358 (1%) | 0% | 28.2 | 642,729 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 May 2024 | 95,000 | 1,141,166 (1%) | 0% | 25.2 | 2,394,798 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 May 2024 | 75,000 | 1,066,166 (1%) | 0% | 25.1 | 1,880,415 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 May 2024 | 57,844 | 1,236,166 (1%) | 0% | 25.1 | 1,453,550 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 22 Mar 2024 | 27,233 | 1,294,010 (1%) | 0% | 22.2 | 605,662 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 22 Mar 2024 | 20,202 | 1,339,832 (1%) | 0% | 22.2 | 449,292 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 22 Mar 2024 | 18,589 | 1,321,243 (1%) | 0% | 22.2 | 413,419 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 14 Mar 2024 | 246,248 | 1,390,644 (1%) | 0% | 0 | Common Stock | ||
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 14 Mar 2024 | 30,610 | 1,360,034 (1%) | 0% | 21.2 | 647,708 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2023 | 51,292 | 1,144,396 (1%) | 0% | 17.9 | 917,614 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2023 | 22,943 | 1,195,688 (1%) | 0% | 17.9 | 410,450 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 516 | 16,069 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 24 Mar 2023 | 26,997 | 1,218,631 (1%) | 0% | 23.7 | 640,369 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 24 Mar 2023 | 18,428 | 1,245,628 (1%) | 0% | 23.7 | 437,112 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 22 Mar 2023 | 20,046 | 1,264,056 (1%) | 0% | 22.9 | 459,254 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 15 Mar 2023 | 197,023 | 1,284,102 (1%) | 0% | 0 | Common Stock | ||
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 658 | 15,553 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 677 | 14,895 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 514 | 14,218 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2022 | 49,980 | 1,087,079 (1%) | 0% | 27.6 | 1,379,948 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2022 | 22,370 | 1,137,059 (1%) | 0% | 27.6 | 617,636 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2022 | 475 | 13,704 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 24 Mar 2022 | 26,200 | 1,159,429 (1%) | 0% | 25.3 | 663,384 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 24 Mar 2022 | 17,884 | 1,185,629 (1%) | 0% | 25.3 | 452,823 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President & CEO | 22 Mar 2022 | 173,144 | 1,203,513 (1%) | 0% | 0 | Common Stock | ||
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2022 | 429 | 13,229 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 16 Feb 2022 | 234,271 | 1,030,369 (1%) | 0% | 0 | Common Stock | ||
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 446 | 12,800 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 23 Sep 2021 | 445,439 | 845,488 (1%) | 0% | 0 | Common Stock | ||
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 23 Sep 2021 | 49,390 | 796,098 (1%) | 0% | 34.8 | 1,716,796 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2021 | 365 | 12,354 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2021 | 58,820 | 400,049 (0%) | 0% | 32.8 | 1,928,708 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2021 | 379 | 11,989 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 24 Mar 2021 | 159,915 | 458,869 (0%) | 0% | 0 | Common Stock | ||
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 436 | 11,610 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Dec 2020 | 3,380 | 11,174 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.17 per share. | 30 Nov 2020 | 7,178 | 16,035 (0%) | 0% | 66.2 | 474,968 | Common Stock |
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 7,178 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 66.29 per share. | 30 Nov 2020 | 7,165 | 18,877 (0%) | 0% | 66.3 | 474,968 | Common Stock |
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 7,165 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 75.77 per share. | 30 Nov 2020 | 5,015 | 12,316 (0%) | 0% | 75.8 | 379,987 | Common Stock |
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2020 | 5,015 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Paul J. Diaz | Director | Sale or transfer of securities back to the company at price $ 109.88 per share. | 30 Nov 2020 | 4,323 | 11,712 (0%) | 0% | 109.9 | 475,011 | Common Stock |
| DaVita Inc | Paul J. Diaz | Director | Sale or transfer of securities back to the company at price $ 109.88 per share. | 30 Nov 2020 | 4,323 | 14,554 (0%) | 0% | 109.9 | 475,011 | Common Stock |
| DaVita Inc | Paul J. Diaz | Director | Sale or transfer of securities back to the company at price $ 109.88 per share. | 30 Nov 2020 | 3,459 | 8,857 (0%) | 0% | 109.9 | 380,075 | Common Stock |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2020 | 430 | 7,301 (0%) | 0% | 0 | Common Stock | |
| DaVita Inc | Paul J. Diaz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2020 | 578 | 6,871 (0%) | 0% | 0 | Common Stock | |
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2020 | 342,040 | 342,040 | - | - | Time-Based Stock Option | ||
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2020 | 339,088 | 339,088 | - | - | Performance-Based Stock Option | ||
| Myriad Genetics, Inc. | Paul J. Diaz | Director, President and CEO | 13 Aug 2020 | 298,954 | 298,954 (0%) | 0% | 0 | Common Stock | ||
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2020 | 4,662 | 0 | - | - | Stock Appreciation Rights | |
| DaVita Inc | Paul J. Diaz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.51 per share. | 08 Jun 2020 | 4,662 | 10,598 (0%) | 0% | 81.5 | 380,000 | Common Stock |
| DaVita Inc | Paul J. Diaz | Director | Sale or transfer of securities back to the company at price $ 88.28 per share. | 08 Jun 2020 | 4,305 | 6,293 (0%) | 0% | 88.3 | 380,045 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges